Analysis of adverse reactions caused by cisatracurium besylate based on the database of Shandong Provincial Center for Adverse Drug Reaction Monitoring
10.3760/cma.j.cn114015-20240419-00273
- VernacularTitle:基于山东省药品不良反应监测中心数据库的苯磺顺阿曲库铵不良反应分析
- Author:
Lili YANG
1
;
Qun ZHAO
;
Jigang SI
;
Ran CUI
;
Lili XU
Author Information
1. 山东省淄博市中心医院药学部，淄博 255036
- Publication Type:Journal Article
- Keywords:
Neuromuscular blocking agents;
Anaphylaxis;
Adverse drug reaction reporting systems;
Retrospective studies;
Cisatracurium besylate;
Shandong Provincial Cen
- From:
Adverse Drug Reactions Journal
2024;26(11):683-688
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical characteristics and treatments of adverse reactions and anaphylaxis induced by cisatracurium besylate, and provide reference for medication safety in clinic.Methods:Adverse reaction reports of cisatracurium besylate in database of Shandong Provincial Center for Adverse Drug Reaction Monitoring between January 1, 2008 and April 18, 2023 were collected and analyzed retrospectively. The adverse reaction terminology was standardized using the preferred terms and system organ class (SOC) in the Medical Dictionary for Regulatory Activities 25.1. The cases of anaphylaxis were selected and graded. The characteristics of all anaphylaxis and treatments of anaphylaxis of grade Ⅱ-Ⅳ were analyzed. Results:A total of 163 adverse reaction reports were included for analysis, involving 201 preferred terms. The top 3 SOCs involved were mainly skin and subcutaneous tissue disorders (133 cases, 66.17%), vascular disorders (14 cases, 6.96%), and immune system disorders(14 cases, 6.96%). One hundred and forty-five patients (89.0%) experienced anaphylaxis, mainly within 10 minutes after medication (115 cases, 79.3%). Of them, 37 (25.5%) patients had anaphylaxis of grade Ⅱ-Ⅳ. The most common initial symptom was circulation system symptoms (19 cases, 51.4%), followed by skin or mucosal signs (12 cases, 32.4%). The main therapeutic drugs included glucocorticoids (27 cases, 73.0%), adrenaline (17 cases, 45.9%), and other vasopressors other than adrenaline (19 cases, 51.4%). All patients showed improvement or recovery in symptoms after treatments.Conclusions:The anaphylaxis caused by cisatracurium besylate mainly occurred within 10 minutes after medication and have a good prognosis. For anaphylaxis classified as grade Ⅱ-Ⅳ, the acute phase treatment drugs mainly include glucocorticoids, adrenaline, and other vasopressors other than adrenaline.
